Show
Sort by
-
Global access and patient safety in the transition to environmentally friendly respiratory inhalers : the Global Initiative for Asthma perspective
-
- Journal Article
- A1
- open access
Global Initiative for Asthma Strategy 2021 : executive summary and rationale for key changes
-
Global Initiative for Asthma Strategy 2021 : executive summary and rationale for key changes
-
- Journal Article
- A1
- open access
Global initiative for Asthma Strategy 2021 : executive summary and rationale for key changes
-
- Journal Article
- A1
- open access
Global Initiative for Asthma Strategy 2021 : executive summary and rationale for key changes
-
- Journal Article
- A1
- open access
Global Initiative for Asthma Strategy 2021 : executive summary and rationale for key changes
-
- Miscellaneous
- open access
Disease-modifying anti-asthmatic drugs
-
ARIA digital anamorphosis : digital transformation of health and care in airway diseases from research to practice
-
- Journal Article
- A1
- open access
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)
-
Cabbage and fermented vegetables : from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19
-
- Journal Article
- A1
- open access
Eosinophilic and noneosinophilic asthma : an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort
-
Staphylococcus aureus and its IgE-inducing enterotoxins in asthma : current knowledge
-
- Journal Article
- A1
- open access
Nrf2-interacting nutrients and COVID-19 : time for research to develop adaptation strategies
-
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma
-
- Journal Article
- A1
- open access
Next-generation ARIA care pathways for rhinitis and asthma : a model for multimorbid chronic diseases
-
GINA 2019 : a fundamental change in asthma management
-
Development of the International Severe Asthma Registry (ISAR) : a modified Delphi study
-
- Journal Article
- A1
- open access
Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies
-
Care pathways for the selection of a biologic in severe asthma
-
- Journal Article
- A2
- open access
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy
-
- Journal Article
- A1
- open access
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme
-
- Journal Article
- A1
- open access
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)
-
Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases
-
Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma